The interplay between tumor-intrinsic KRT6A and host-derived immune-nutritional status (PNI) defines prognosis in resectable PDAC
Open Access
- 23 May 2026
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
Current anatomic staging inadequately predicts outcomes in resectable pancreatic ductal adenocarcinoma (PDAC). This study integrates tumor-intrinsic KRT6A expression with host-derived prognostic nutritional index (PNI) to develop a novel prognostic model. This retrospective study enrolled 105 patients who underwent pancreaticoduodenectomy for histologically confirmed PDAC between January 2019 and December 2024. KRT6A expression was quantified by immunohistochemistry using computer-assisted image analysis. PNI was calculated as serum albumin (g/L) + 5 × lymphocyte count (10⁹/L). The primary endpoint was disease-free survival (DFS). Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors. A prognostic nomogram (KSI-Nomo) integrating KRT6A and PNI was constructed and validated using time-dependent ROC curves, calibration plots, and decision curve analysis. Risk stratification was performed based on nomogram total points. KRT6A expression was significantly elevated in poorly differentiated tumors and functionally promoted PDAC cell migration and invasion in vitro. Multivariate analysis identified KRT6A expression (HR = 6.337, 95% CI: 1.733-9.540, P = 0.034) and PNI (HR = 0.953, 95% CI: 0.245-1.702, P = 0.014) as the sole independent prognostic factors for DFS, outperforming conventional inflammatory indices (NLR, PLR, SII) and TNM staging. The KRT6A-PNI nomogram demonstrated excellent discriminative accuracy with AUC values of 0.838 (1-year), 0.836 (2-year), and 0.969 (3-year). Calibration curves showed good agreement between predicted and observed survival probabilities. Decision curve analysis confirmed superior net clinical benefit compared to treat-all or treat-none strategies. Risk stratification identified three distinct prognostic groups: low-risk (30% of patients, 3-year DFS rate 52.3%), intermediate-risk (40%, 38.6%), and high-risk (30%, 12.4%) (log-rank P < 0.001). The KRT6A-PNI model provides superior risk stratification for resectable PDAC, enabling personalized treatment decisions.Keywords
This publication has 27 references indexed in Scilit:
- Integrated transcriptome and single-cell RNA sequencing analysis revealed the prognostic significance of GBP4 in pancreatic adenocarcinomaTranslational Oncology, 2025
- Pancreatic Cancer Surveillance and Survival of High-Risk IndividualsJAMA Oncology, 2024
- Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC)Cancer Pathogenesis and Therapy, 2024
- Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinomaScientific Reports, 2024
- The prognostic value of immune-nutritional status in metastatic colorectal cancer: Prognostic Nutritional Index (PNI)Supportive Care in Cancer, 2024
- The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexiaCancer Cell, 2024
- Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trialThe Lancet Gastroenterology & Hepatology, 2024
- SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancerCell Reports, 2023
- A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarcinomaCarcinogenesis, 2023
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaNature Genetics, 2015